

10/582316

Express Mail No. EV668295389US

Date of deposit: June 8, 2006

SLR:dm 06/08/06 5585-68213-02 536280 RCD/P103734US

10/20 Rec'd PCT/PTO 08 JUN 2006 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Xin Lu and Elizabeth Slee

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: TUMOUR SUPPRESSOR PROTEIN

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 5585-68213-02

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

cc: Docketing

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.D./ (08/27/2008)

SLR:dm 06/08/06 5585-68213-02 523176 RCD/P103734US

Express Mail No. EV668295389US

Date of Deposit: June 8, 2006

| | | |
|--|------------------------|---------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | Attorney Docket Number | 5585-68213-02 |
| | Application Number | Currently unknown |
| | Filing Date | 10/582316 June 8, 2006 |
| | First Named Inventor | Lu |
| | Art Unit | Not yet assigned |
| | Examiner Name | Not yet assigned |

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

| Examiner's Initials* | Cite No. (optional) | Number | Publication Date | Name of Applicant or Patentee |
|-------------------------|------------------------|--------|------------------|-------------------------------|
| | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Country | Number | Publication Date | Name of Applicant or Patentee |
|-------------------------|------------------------|---------|-----------------|------------------|--------------------------------------|
| | | WIPO | WO 02/12325 A2 | 02/14/2002 | Ludwig Institute for Cancer Research |
| | | WIPO | WO 03/000843 A2 | 01/03/2003 | The Brigham & Women's Hospital, Inc. |
| | | | | | |

OTHER DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | |
|-------------------------|------------------------|--|
| | | Database EMBL 'Online! Accession No. BC032298 (2002). |
| | | Bergamaschi et al., "iASPP Oncoprotein is a Key Inhibitor of p53 Conserved from Worm to Human," <i>Nature Genetics</i> 33:162-167 (2003). |
| | | Yang et al., "Identification of a Novel Inhibitor of Nuclear Factor- κ B, RelA-Associated Inhibitor," <i>J. Biol. Chem.</i> 274:15662-15670 (1999). |
| | | |
| | | |
| | | |
| | | |

EXAMINER
SIGNATURE: /Minh Tam Davis/ (08/27/2008)

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.